TB-500 Frag
The cheap small piece of TB-500. The chemistry is real, the healing data is not, and the savings are smaller than the vial price suggests.
What it is
TB-500 Frag is the short actin-binding piece of thymosin beta-4 sold as a budget stand-in for TB-500, for the same recovery and flexibility goals. The honest read is that the fragment keeps the lab chemistry and loses the track record: no human data, and people who have run both mostly say the full peptide works better.
The person who buys this is price-shopping a healing stack: they want the body-wide recovery and flexibility that TB-500 is known for, they have seen the fragment at a fraction of the price per vial, and they are hoping the active piece is all they need. Some are curious experimenters who already run BPC-157 and want to add the TB-4 side cheaply. If you have an actual injury you are trying to heal, this is not where to economize; the full peptide or the BPC-157 + TB-500 blend is the better bet for the money you are about to spend anyway.
If it does anything, it looks like the full peptide's effect at lower volume: looser movement and less morning stiffness over the first two to three weeks, a little faster recovery between sessions, and a slow improvement in a nagging soft-tissue problem by weeks four to six. The common report is weaker: people who have run full TB-500 say the fragment gives them some of the looseness and little of the healing. It will not do anything for a specific sore spot that BPC-157 would not do better, and it is not a painkiller.
The community pattern is a loading phase of 2 to 2.5 mg subQ (just under the skin with an insulin needle) twice a week for four to six weeks, then about 2 mg once a week until the injury has settled, then stop. The fragment is not known to stop working; the drop to a weekly dose just matches the dose to the job. In the belly, rotating sites; some inject nearer the injury, though it works body-wide. Here is the math to do before you buy: the fragment is dosed at 2 to 2.5 mg a shot, two to five times the up-to-1 mg maintenance shot of full TB-500. A 10 mg vial is five shots at 2 mg, under three weeks of loading, so a six week loading phase is two or three vials. Price that whole cycle against a full TB-500 cycle before deciding the fragment is the bargain. The mistakes: assuming the cheaper vial means a cheaper cycle, and running it alone for a specific injury instead of with BPC-157.
The evidence for the fragment is a chemistry fact and nothing else. The seven-amino-acid LKKTETQ region is where thymosin beta-4 binds actin, the protein cells use to move and rebuild, and that binding holds up in the lab. Every wound-healing and heart study that gives TB-500 its reputation used the full 43-amino-acid molecule, in animals, with thin human data even there. Nobody has shown the fragment heals anything in an animal or a person. It is lower on the evidence ladder than TB-500, which is itself promising but not proven.
For an injury, buy full TB-500 or the BPC-157 + TB-500 blend and dose it properly. For a stubborn sore spot, BPC-157 alone does more than any TB-4 product. For inflammation on top of injury, KPV. The fragment makes sense only as a cheap experiment for someone with no specific injury who wants to see whether the looseness and recovery effect shows up for them.
What people use it for
Actin binding, the real part
Early daysThe fragment contains the LKKTETQ sequence that lets thymosin beta-4 grab actin, the protein cells use to move and rebuild tissue, and that binding is confirmed in the lab. This is the entire scientific basis for the product. It tells you the piece is active in a test tube, not that it heals anything.
Tissue healing
Early daysThe wound-closure, heart-repair, and blood-vessel studies behind TB-500's reputation used the full 43-amino-acid peptide in animals. No study, animal or human, has tested the fragment for healing. The gap is not a technicality: the full molecule has regions the fragment drops, and nobody knows what they contribute.
Fragment versus full peptide
Early daysThere is no head-to-head study. What exists is consistent community comparison: people who have run both report the fragment gives some of the looseness and less of the recovery. Combined with the higher per-shot dose, that makes it the weaker option per dollar as well as per milligram.
How people use it
Safety, in brief
Things people sometimes notice
- Soreness or a small bump where you inject, the one effect everyone reports
- A mild headache or a wave of tiredness in the hours after a shot for some people
- Nothing else that anyone has characterized; the fragment has not been studied in people
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
The labels and studies behind this page. Each link opens the original on PubMed, DailyMed or ClinicalTrials.gov.
- Biological activities of thymosin beta4 defined by active sites in short peptide sequences
- Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice
- Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro